Page 2 - Christopher Posner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

22.01.2024 - – Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara . Seite 1

Christopher posnerCara therapeutics incChief executive officerCara therapeutics chartAra therapeutics kursAra therapeutics aktie

Itch treater Cara cuts 50% of team to extend runway into 2026

Itch treater Cara cuts 50% of team to extend runway into 2026
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Christopher posnerVifor pharmaCara therapeuticsHealthcare royalty

Cara Therapeutics Reports Third Quarter 2023 Financial

– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all.

Harrisonm bainsHelenm boudreauIris francesconiAnnie spinettaChristopher posnerDevelopment rd expensesEnteris biopharma incCenters for medicare medicaid servicesMaruishi pharmaceuticals coExchange commissionCompany board of directorsAudit committeeCara therapeutics incCompany annual report on formNeuropathic itch patient surveyHealthcare royalty

Cara Therapeutics Reports Third Quarter 2023 Financial Results

– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025–

Helenm boudreauHarrisonm bainsAnnie spinettaChristopher posnerIris francesconiCara therapeutics incDevelopment rd expensesMaruishi pharmaceuticals coCompany annual report on formExchange commissionCompany board of directorsEnteris biopharma incNeuropathic itch patient surveyAudit committeeCenters for medicare medicaid servicesHealthcare royalty

Cara Therapeutics in royalty interest purchase pact with HealthCare Royalty

Cara Therapeutics Inc., a Stamford-headquartered commercial-stage biopharmaceutical company focused on creating a new treatment paradigm to improve the lives of patients suffering from pruritus, has entered into a royalty interest purchase and sale agreement with HealthCare Royalty (HCRx), also based in Stamford.

Christopher posnerCara therapeutics incMaruishi pharmaceutical coCara therapeuticsHealthcare royaltyMaruishi pharmaceutical